phase I clinical study
Caris Life Sciences, Essa Pharma Ink Liquid Biopsy Partnership for Prostate Cancer Trial
Essa will use Caris' blood-based sequencing tests to assess the genetic profiles of mCRPC patients enrolled in a Phase I trial of the firm's investigational agent.
FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC
This is the first time the FDA has approved a drug specifically for NSCLC patients who harbor rare EGFR Exon20 insertion mutations.
Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.
Hummingbird Bioscience, Novogene Partner to ID Cancer Patients With NRG1 Fusions in China
Novogene will use next-generation sequencing to identify solid tumor patients eligible to enroll in clinical trials of Hummingbird's anti-HER3 agent, HMBD-001.
MapKure, Personalis Partner to Screen Patients for BRAF Inhibitor Trial
Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study.